Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia

Matteo Cesari; Roger A. Fielding; Marco Pahor; Bret Goodpaster; Marc Hellerstein; Gabor A. van Kan; Stefan D. Anker; Seward Rutkove; J. Willem Vrijbloed; Maria Isaac; Yves Rolland; Christine M'Rini; Mylène Aubertin-Leheudre; Jesse M. Cedarbaum; Mauro Zamboni; Cornell C. Sieber; Didier Laurent; William J. Evans; Ronenn Roubenoff; John E. Morley; Bruno Vellas; Gabor Abellan van Kan; Sandrine Andrieu; Stefan D. Anker; Patricia Anthony; Christian Asbrand; Myl̀ne Aubertin-Leheudre; Sebastien Barbart-Artigas; Olivier Benichou; Cécile Bonhomme; Pascale Borensztein; Denis Breuillé; Sergio Castro Henriquez; Jesse M. Cedarbaum; Matteo Cesari; Patricia Chatelain; Wm Cameron Chumlea; Richard V. Clark; Capucine de Meynard; William J. Evans; Gary Fanjiang; Luigi Ferrucci; Roger A. Fielding; Philippe Garnier; Sophie Gillette-Guyonnet; Bret Goodpaster; Marie Françoise Gros; Luis Miguel F Gutierrez Robledo; Marc Hellerstein; Kelly Krohn; Maria Isaac; Didier Laurent; Menghua Luo; Hélène Matheix-Fortunet; Inge Mohede; John E. Morley; Christine M'Rini; Ramon Navarro; Bruno Oesch; Reinhard Ommerborn; Marco Pahor; Patrick Ritz; Yves Rolland; Daniel Rooks; Ronnen Roubenoff; Fariba Roughead; Seward Rutkove; Cornel C. Sieber; Michèle Storrs-Malibat; Stephanie Studenski; Yannis Tsouderos; Bruno Vellas; Sjors Verlaan; Stephan von Haehling; J. Willem Vrijbloed; Sander Wijers; Mauro Zamboni

doi:10.1007/s13539-012-0078-2

Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia

Matteo Cesari, Roger A. Fielding, Marco Pahor, Bret Goodpaster, Marc Hellerstein, Gabor A. van Kan, Stefan D. Anker, Seward Rutkove, J. Willem Vrijbloed, Maria Isaac, Yves Rolland, Christine M'Rini, Mylène Aubertin-Leheudre, Jesse M. Cedarbaum, Mauro Zamboni, Cornell C. Sieber, Didier Laurent, William J. Evans, Ronenn Roubenoff, John E. MorleyBruno Vellas, Gabor Abellan van Kan, Sandrine Andrieu, Stefan D. Anker, Patricia Anthony, Christian Asbrand, Myl̀ne Aubertin-Leheudre, Sebastien Barbart-Artigas, Olivier Benichou, Cécile Bonhomme, Pascale Borensztein, Denis Breuillé, Sergio Castro Henriquez, Jesse M. Cedarbaum, Matteo Cesari, Patricia Chatelain, Wm Cameron Chumlea, Richard V. Clark, Capucine de Meynard, William J. Evans, Gary Fanjiang, Luigi Ferrucci, Roger A. Fielding, Philippe Garnier, Sophie Gillette-Guyonnet, Bret Goodpaster, Marie Françoise Gros, Luis Miguel F Gutierrez Robledo, Marc Hellerstein, Kelly Krohn, Maria Isaac, Didier Laurent, Menghua Luo, Hélène Matheix-Fortunet, Inge Mohede, John E. Morley, Christine M'Rini, Ramon Navarro, Bruno Oesch, Reinhard Ommerborn, Marco Pahor, Patrick Ritz, Yves Rolland, Daniel Rooks, Ronnen Roubenoff, Fariba Roughead, Seward Rutkove, Cornel C. Sieber, Michèle Storrs-Malibat, Stephanie Studenski, Yannis Tsouderos, Bruno Vellas, Sjors Verlaan, Stephan von Haehling, J. Willem Vrijbloed, Sander Wijers, Mauro Zamboni

Research output: Contribution to journal › Article › peer-review

153 Scopus citations

Abstract

Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7-8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.

Original language	English (US)
Pages (from-to)	181-190
Number of pages	10
Journal	Journal of Cachexia, Sarcopenia and Muscle
Volume	3
Issue number	3
DOIs	https://doi.org/10.1007/s13539-012-0078-2
State	Published - 2012
Externally published	Yes

ASJC Scopus subject areas

Orthopedics and Sports Medicine
Physiology (medical)

Access to Document

10.1007/s13539-012-0078-2

Cite this

Cesari, M., Fielding, R. A., Pahor, M., Goodpaster, B., Hellerstein, M., van Kan, G. A., Anker, S. D., Rutkove, S., Vrijbloed, J. W., Isaac, M., Rolland, Y., M'Rini, C., Aubertin-Leheudre, M., Cedarbaum, J. M., Zamboni, M., Sieber, C. C., Laurent, D., Evans, W. J., Roubenoff, R., ... Zamboni, M. (2012). Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 3(3), 181-190. https://doi.org/10.1007/s13539-012-0078-2

Cesari, M, Fielding, RA, Pahor, M, Goodpaster, B, Hellerstein, M, van Kan, GA, Anker, SD, Rutkove, S, Vrijbloed, JW, Isaac, M, Rolland, Y, M'Rini, C, Aubertin-Leheudre, M, Cedarbaum, JM, Zamboni, M, Sieber, CC, Laurent, D, Evans, WJ, Roubenoff, R, Morley, JE, Vellas, B, van Kan, GA, Andrieu, S, Anker, SD, Anthony, P, Asbrand, C, Aubertin-Leheudre, M, Barbart-Artigas, S, Benichou, O, Bonhomme, C, Borensztein, P, Breuillé, D, Henriquez, SC, Cedarbaum, JM, Cesari, M, Chatelain, P, Chumlea, WC, Clark, RV, de Meynard, C, Evans, WJ, Fanjiang, G, Ferrucci, L, Fielding, RA, Garnier, P, Gillette-Guyonnet, S, Goodpaster, B, Gros, MF, Gutierrez Robledo, LMF, Hellerstein, M, Krohn, K, Isaac, M, Laurent, D, Luo, M, Matheix-Fortunet, H, Mohede, I, Morley, JE, M'Rini, C, Navarro, R, Oesch, B, Ommerborn, R, Pahor, M, Ritz, P, Rolland, Y, Rooks, D, Roubenoff, R, Roughead, F, Rutkove, S, Sieber, CC, Storrs-Malibat, M, Studenski, S, Tsouderos, Y, Vellas, B, Verlaan, S, von Haehling, S, Vrijbloed, JW, Wijers, S & Zamboni, M 2012, 'Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia', Journal of Cachexia, Sarcopenia and Muscle, vol. 3, no. 3, pp. 181-190. https://doi.org/10.1007/s13539-012-0078-2

@article{2245b96f14ae48e7bade137b52940b5d,

title = "Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia",

abstract = "Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7-8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.",

author = "Matteo Cesari and Fielding, {Roger A.} and Marco Pahor and Bret Goodpaster and Marc Hellerstein and {van Kan}, {Gabor A.} and Anker, {Stefan D.} and Seward Rutkove and Vrijbloed, {J. Willem} and Maria Isaac and Yves Rolland and Christine M'Rini and Myl{\`e}ne Aubertin-Leheudre and Cedarbaum, {Jesse M.} and Mauro Zamboni and Sieber, {Cornell C.} and Didier Laurent and Evans, {William J.} and Ronenn Roubenoff and Morley, {John E.} and Bruno Vellas and {van Kan}, {Gabor Abellan} and Sandrine Andrieu and Anker, {Stefan D.} and Patricia Anthony and Christian Asbrand and My{\`l}ne Aubertin-Leheudre and Sebastien Barbart-Artigas and Olivier Benichou and C{\'e}cile Bonhomme and Pascale Borensztein and Denis Breuill{\'e} and Henriquez, {Sergio Castro} and Cedarbaum, {Jesse M.} and Matteo Cesari and Patricia Chatelain and Chumlea, {Wm Cameron} and Clark, {Richard V.} and {de Meynard}, Capucine and Evans, {William J.} and Gary Fanjiang and Luigi Ferrucci and Fielding, {Roger A.} and Philippe Garnier and Sophie Gillette-Guyonnet and Bret Goodpaster and Gros, {Marie Fran{\c c}oise} and {Gutierrez Robledo}, {Luis Miguel F} and Marc Hellerstein and Kelly Krohn and Maria Isaac and Didier Laurent and Menghua Luo and H{\'e}l{\`e}ne Matheix-Fortunet and Inge Mohede and Morley, {John E.} and Christine M'Rini and Ramon Navarro and Bruno Oesch and Reinhard Ommerborn and Marco Pahor and Patrick Ritz and Yves Rolland and Daniel Rooks and Ronnen Roubenoff and Fariba Roughead and Seward Rutkove and Sieber, {Cornel C.} and Mich{\`e}le Storrs-Malibat and Stephanie Studenski and Yannis Tsouderos and Bruno Vellas and Sjors Verlaan and {von Haehling}, Stephan and Vrijbloed, {J. Willem} and Sander Wijers and Mauro Zamboni",

year = "2012",

doi = "10.1007/s13539-012-0078-2",

language = "English (US)",

volume = "3",

pages = "181--190",

journal = "Journal of Cachexia, Sarcopenia and Muscle",

issn = "2190-5991",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia

AU - Cesari, Matteo

AU - Fielding, Roger A.

AU - Pahor, Marco

AU - Goodpaster, Bret

AU - Hellerstein, Marc

AU - van Kan, Gabor A.

AU - Anker, Stefan D.

AU - Rutkove, Seward

AU - Vrijbloed, J. Willem

AU - Isaac, Maria

AU - Rolland, Yves

AU - M'Rini, Christine

AU - Aubertin-Leheudre, Mylène

AU - Cedarbaum, Jesse M.

AU - Zamboni, Mauro

AU - Sieber, Cornell C.

AU - Laurent, Didier

AU - Evans, William J.

AU - Roubenoff, Ronenn

AU - Morley, John E.

AU - Vellas, Bruno

AU - van Kan, Gabor Abellan

AU - Andrieu, Sandrine

AU - Anker, Stefan D.

AU - Anthony, Patricia

AU - Asbrand, Christian

AU - Aubertin-Leheudre, Myl̀ne

AU - Barbart-Artigas, Sebastien

AU - Benichou, Olivier

AU - Bonhomme, Cécile

AU - Borensztein, Pascale

AU - Breuillé, Denis

AU - Henriquez, Sergio Castro

AU - Cedarbaum, Jesse M.

AU - Cesari, Matteo

AU - Chatelain, Patricia

AU - Chumlea, Wm Cameron

AU - Clark, Richard V.

AU - de Meynard, Capucine

AU - Evans, William J.

AU - Fanjiang, Gary

AU - Ferrucci, Luigi

AU - Fielding, Roger A.

AU - Garnier, Philippe

AU - Gillette-Guyonnet, Sophie

AU - Goodpaster, Bret

AU - Gros, Marie Françoise

AU - Gutierrez Robledo, Luis Miguel F

AU - Hellerstein, Marc

AU - Krohn, Kelly

AU - Isaac, Maria

AU - Laurent, Didier

AU - Luo, Menghua

AU - Matheix-Fortunet, Hélène

AU - Mohede, Inge

AU - Morley, John E.

AU - M'Rini, Christine

AU - Navarro, Ramon

AU - Oesch, Bruno

AU - Ommerborn, Reinhard

AU - Pahor, Marco

AU - Ritz, Patrick

AU - Rolland, Yves

AU - Rooks, Daniel

AU - Roubenoff, Ronnen

AU - Roughead, Fariba

AU - Rutkove, Seward

AU - Sieber, Cornel C.

AU - Storrs-Malibat, Michèle

AU - Studenski, Stephanie

AU - Tsouderos, Yannis

AU - Vellas, Bruno

AU - Verlaan, Sjors

AU - von Haehling, Stephan

AU - Vrijbloed, J. Willem

AU - Wijers, Sander

AU - Zamboni, Mauro

PY - 2012

Y1 - 2012

N2 - Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7-8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.

AB - Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7-8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.

UR - http://www.scopus.com/inward/record.url?scp=84865765098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865765098&partnerID=8YFLogxK

U2 - 10.1007/s13539-012-0078-2

DO - 10.1007/s13539-012-0078-2

M3 - Article

C2 - 22865205

AN - SCOPUS:84865765098

SN - 2190-5991

VL - 3

SP - 181

EP - 190

JO - Journal of Cachexia, Sarcopenia and Muscle

JF - Journal of Cachexia, Sarcopenia and Muscle

IS - 3

ER -

Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this